Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA Trial): A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME or XIENCE Xpedition) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms AIDA
- 29 Mar 2017 Results of preliminary analysis assessing early safety and efficacy (n=1793) (Data cut off December 16, 2016 ) published in the New England Journal of Medicine
- 29 Dec 2015 Planned End Date changed from 1 Sep 2020 to 1 Dec 2020, as reported by ClinicalTrials.gov record.
- 29 Dec 2015 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017, as reported by ClinicalTrials.gov record.